Rethinking Clinical Trials

JULY 9, 2023

Discussion Themes Motivating patients to engage in self-management of health conditions is a challenge, irrespective of whether the intervention is delivered in person or remotely. Designing interventions that can meet everyone’s needs can be a challenge in a study that involves rural/urban and racial/ethnic diversity.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

Rethinking Clinical Trials

NOVEMBER 21, 2023

In Years 2-5 (UH3 Phase) the aims were to conduct and evaluate a pragmatic patient-level randomized intervention across 3 healthcare systems to improve adherence to chronic cardiovascular (CV) medications. Patients could reply with Done and the message reminders would stop. The study would then recalculate the gaps.

Clinical Trials 141

Clinical Trials Clinical Trials Trials Development 141

Rethinking Clinical Trials

DECEMBER 6, 2022

Making lifestyle changes is difficult especially for people living with chronic diseases, where healthy behaviors could make a big difference. This study asks how can we better facilitate health behaviors in patients with chronic diseases and can we leverage technology? Medication adherence can be a barrier to effectiveness.

Trials 130

Trials Clinical Trials Clinical Trials Compliance 130

Rethinking Clinical Trials

DECEMBER 12, 2023

Patients who were eligible had been hospitalized at least 12 hours but no more than 96 hours, age 55 and older with at least one Dartmouth Atlas chronic condition, or they were age 80 or older. It is something we are thinking about a lot in the outpatient trial. Clinicians could receive prompts on an almost daily basis.

Trials 130

Trials Medicine Clinical Trials Clinical Trials 130

Delveinsight

JULY 22, 2020

Since the data is collected for a long period of time, the doctor can easily evaluate the current and past medical conditions. Patients do not need to visit hospitals to get the basic status of their health conditions. This helps in analysis and diagnosis of health conditions like cardiovascular disease. Services In Remote Area.

Doctors 59

Doctors Doctor Marketing Production 59

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. The model for making a profit from medicine is geared towards delivering medicines regularly, usually for chronic conditions.

Gene Therapy 131

Gene Therapy Gene Marketing Development 131

XTalks

AUGUST 17, 2020

Why not use a biologic platform to essentially do in vivo cell therapy directly in the patient?”. In addition to these targets in Cue’s portfolio, there are a couple of others that the company is working on that currently remain undisclosed. “The

Protein 98

Protein Engineer Immune Response In-Vivo 98